Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

Michael Rytting

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Child and adolescent patients who are diagnosed with acute lymphoblastic leukemia (ALL), both of B-cell or T-cell phenotype, have excellent outcomes when treated with various multiagent chemotherapy regimens. The presentation and early medical management of these young patients are remarkably similar to the initial management of newly diagnosed adult ALL patients, though the eventual chemotherapy may be quite different. Subgroups of childhood and adolescent ALL with poor prognosis are now regularly recognized by cytogenetic and molecular studies as well as by flow cytometry. Minimal residual disease measured at various times in therapy is highly prognostic and may be used to guide therapy. Very high risk patients as well as patients with relapsed or refractory disease may benefit from newer antibody and cell therapies.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages185-192
Number of pages8
DOIs
StatePublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Keywords

  • Acute lymphoblastic leukemia
  • Immunotherapy
  • Minimal residual disease (MRD)
  • Protocol therapy
  • T-cell

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents'. Together they form a unique fingerprint.

Cite this